SGC0946

CAT: 0804-HY-15650-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15650-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SGC0946 is a selective DOT1L inhibitor with an IC50 value of 0.3 nM. By inhibiting DOT1L, SGC0946 can induce G1 phase arrest, suppress cell self-renewal and metastatic potential, and induce cell differentiation in cancer cells. SGC0946 can be used in the research of tumors such as leukemia and breast cancer, and also serves as a probe to further investigate the cellular mechanisms of DOT1L in normal and diseased cells[1][2][3].
CAS Number
[1561178-17-3]
UNSPSC
12352005
Hazard Statement
H301
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SGC0946.html
Purity
99.68
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC(C)(C1=CC=C(C=C1)NC(NCCCN(C[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C4=C(C(Br)=C3)C(N)=NC=N4)O2)C(C)C)=O)C
Molecular Formula
C28H40BrN7O4
Molecular Weight
618.57
Precautions
H301
References & Citations
[1]Yu W, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288. |[2]Zhang X, et al. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. J Hematol Oncol. 2017 Jan 23;10 (1) :29. |[3]Zhang L, et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget. 2014 Nov 15;5 (21) :10665-77.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DOT1L

Alternative Products

CatalogName
2448-5SGC0946
MF-0118656-01SGC0946 TFA
bs-60101C-01SGC0946 --- DOT1L inhibitor

Popular Products